Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

Phase 1

Terminated

Conditions: Squamous Cell Carcinoma of the Head and Neck
Adenosquamous Cell Carcinoma
Basaloid Squamous Cell Carcinoma
Undifferentiated Carcinoma

Interventions: Drug: Abraxane
Drug: Erbitux
Drug: Carboplatin
Radiation: Intensity Modulated Radiation Therapy

First Posted Date: 2007-12-11

Last Posted Date: 2017-11-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 29

Registration Number: NCT00570674

Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma

Phase 2

Terminated

Conditions: Melanoma (Skin)

Interventions: Drug: carboplatin
Drug: temozolomide
Drug: paclitaxel

First Posted Date: 2007-12-06

Last Posted Date: 2015-12-30

Lead Sponsor: Mayo Clinic

Target Recruit Count: 12

Registration Number: NCT00568451

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma

Phase 3

Completed

Conditions: Localized Resectable Neuroblastoma
Localized Unresectable Neuroblastoma
Recurrent Neuroblastoma
Regional Neuroblastoma
Stage 4 Neuroblastoma
Stage 4S Neuroblastoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Radiation: External Beam Radiation Therapy
Biological: Filgrastim
Drug: Isotretinoin
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Drug: Topotecan Hydrochloride
Drug: Thiotepa
Drug: Vincristine Sulfate Liposome

First Posted Date: 2007-12-05

Last Posted Date: 2022-04-28

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 665

Registration Number: NCT00567567

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Valley Children's Hospital, Madera, California, United States
🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States

and more 187 locations

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3

Active, not recruiting

Conditions: Fallopian Tube Mucinous Adenocarcinoma
Ovarian Clear Cell Adenocarcinofibroma
Ovarian Serous Adenocarcinoma
Primary Peritoneal Undifferentiated Carcinoma
Undifferentiated Carcinoma
Clear Cell Adenocarcinoma
Fallopian Tube Clear Cell Adenocarcinoma
Ovarian Brenner Tumor
Ovarian Clear Cell Adenocarcinoma
Ovarian Transitional Cell Carcinoma

Interventions: Drug: Carboplatin
Biological: Bevacizumab
Drug: Docetaxel
Drug: Gemcitabine Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2007-11-30

Last Posted Date: 2024-12-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1052

Registration Number: NCT00565851

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
🇺🇸
Sanford Bismarck Medical Center, Bismarck, North Dakota, United States
🇺🇸
Sanford Broadway Medical Center, Fargo, North Dakota, United States

and more 709 locations

FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Malignant Pleural Effusion
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Drug: carboplatin
Drug: docetaxel
Drug: gemcitabine hydrochloride
Drug: paclitaxel
Procedure: computed tomography
Procedure: positron emission tomography
Radiation: fludeoxyglucose F 18
Other: imaging biomarker analysis

First Posted Date: 2007-11-28

Last Posted Date: 2017-02-10

Lead Sponsor: University of Washington

Target Recruit Count: 55

Registration Number: NCT00564733

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Harborview Medical Center, Seattle, Washington, United States

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: Erlotinib
Drug: Carboplatin
Drug: Paclitaxel
Radiation: Radiation Therapy

First Posted Date: 2007-11-26

Last Posted Date: 2019-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 68

Registration Number: NCT00563784

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer

Phase 1

Withdrawn

Conditions: Ovarian Cancer

First Posted Date: 2007-11-21

Last Posted Date: 2017-11-20

Lead Sponsor: University of Texas Southwestern Medical Center

Registration Number: NCT00562185

Locations: 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States

Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors

Phase 2

Completed

Conditions: Tumor
Epithelial Ovarian Cancer
Cervix Diseases
Primary Peritoneal Carcinoma
Cancer
Uterine Disease
Neoplasms, Ovarian

Interventions: Drug: pazopanib (GW786034)
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2007-11-21

Last Posted Date: 2012-03-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT00561795

Locations: 🇩🇪
GSK Investigational Site, Essen, Nordrhein-westfalen, Germany

Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Phase 3

Active, not recruiting

Conditions: Extraocular Retinoblastoma

Interventions: Procedure: Autologous Bone Marrow Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide
Biological: Filgrastim
Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Radiation: Radiation Therapy
Drug: Thiotepa
Drug: Vincristine Sulfate

First Posted Date: 2007-11-07

Last Posted Date: 2024-10-22

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 60

Registration Number: NCT00554788

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 70 locations

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: erlotinib hydrochloride
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Radiation: radiation therapy

First Posted Date: 2007-11-04

Last Posted Date: 2018-01-31

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 78

Registration Number: NCT00553462

Locations: 🇺🇸
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Heartland Regional Medical Center, Saint Joseph, Missouri, United States

and more 96 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy